Introduction
Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and crossreferenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.
The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).
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Signaling by TGF-beta Receptor Complex in Cancer ↗ Stable identifier: R-HSA-3304351
Diseases: cancer
Signaling by the TGF-beta receptor complex is tumor suppressive, as it inhibits cell growth and promotes cell differentiation and apoptosis (Shipley et al. 1986 , Hannon et al. 1994 , Datto et al. 1995 , Chen et al. 2002 , Azar et al. 2009 ). TGF-beta signaling is frequently impaired in cancer, mostly through SMAD4 gene deletion or loss-of-function mutations, which are especially frequent in pancreatic cancer (Hahn et al. 1996 , Shi et al. 1997 , Fleming et al. 2013 . Signaling by TGF-beta receptor complex can also be disrupted by loss-of-function mutations in SMAD2 and SMAD3 (Fleming et al. 2013) or loss-of-function mutations in TGFBR2 (TGF-beta receptor II) (Markowitz et al. 1995 , Garrigue-Antar et al. 1995 , Parsons et al. 1995 , Grady et al. 1999 or TGFBR1 (TGF-beta receptor I) (Chen et al. 1998 .
In advanced cancer, signaling by TGF-beta may be tumor promoting, as it induces epithelial-to-mesenchymal transition (EMT), thereby increasing invasiveness (Cui et al. 1996 , Guasch et al. 2007 , reviewed by Heldin et al. 2012 ).
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Loss of Function of SMAD2/3 in Cancer ↗ Location: Signaling by TGF-beta Receptor Complex in Cancer
Stable identifier: R-HSA-3304349
Diseases: cancer
Loss-of-function of SMAD2 and SMAD3 in cancer occurs less frequently than the loss of SMAD4 function and was studied in most detail in colorectal cancer (Fleming et al. 2013 ).
Similarly to SMAD4, coding sequence mutations in SMAD2 and SMAD3 in cancer cluster in the MH2 do- Chacko, BM., Qin, B., Correia, JJ., Lam, SS., de Caestecker, MP., Lin, K. (2001) . The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization. Nat. Struct. Biol., 8, 
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